Trial Profile

Prospective, randomised, open-label, multicentre, active drug controlled, parallel group design clinical trial of the efficacy and safety of beclomethasone dipropionate 400 mcg + formoterol 24 mcg pMDI [pressurised metered-dose inhaler] via hydrofluoroalkane-134a (Foster) vs. fluticasone propionate 500 mcg + salmeterol xinafoate 100 mcg DPI [dry powder inhaler] (Seretide Diskus) in the 6 months stepdown treatment of adult patients with controlled asthma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Beclometasone/formoterol (Primary) ; Salmeterol/fluticasone propionate
Indications Asthma
Focus Therapeutic Use
Acronyms FORTE
Sponsors Chiesi Farmaceutici

21 Apr 2012 Planned number of patients changed from 382 to 450 as reported by European Clinical Trials Database.
27 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
27 Apr 2010 Actual end date (1 Mar 2010) added as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com